BFLY Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
FDA AI ClearanceFDA clearance of the blind-sweep GA AI tool provides durable regulatory validation for Butterfly's AI capabilities, lowering clinical adoption barriers. This credential supports enterprise integrations, payer/provider acceptance, and long-term differentiation in point-of-care ultrasound platforms.
Modest Leverage And Cash RunwayLow debt relative to equity and a substantial cash position give Butterfly financial flexibility to fund product roadmap, enterprise rollouts, and AI investments without immediate dilution. This balance-sheet strength supports multi-quarter execution cadence and reduces near-term refinancing risk.
Embedded & Software TractionRapid Embedded revenue growth and early enterprise Compass AI wins indicate a shift toward recurring, higher-margin software income. Combined with partner ecosystem expansion and security certifications, this raises the prospect of stickier revenue and scalable enterprise monetization over the coming quarters.
Bears Say
Ongoing Cash BurnDespite improvements, persistent negative operating and free cash flow means Butterfly must continue funding operations or materially improve margins. Ongoing losses constrain reinvestment flexibility, increase dependence on capital markets, and remain a structural risk until operations generate sustained positive cash flow.
Embedded Concentration & Timing RiskHeavy reliance on one large partner for recent Embedded gains creates concentration and timing risk. Confidential, long development cycles for other partners make Embedded revenue lumpy and uncertain, potentially delaying predictable software scale and the expected margin benefits.
EU Regulatory UncertaintyA shortened RoHS exemption recommendation in the EU introduces persistent regulatory uncertainty for handheld ultrasound sales and supply. This can complicate European commercialization, prompt additional compliance costs, and delay market expansion versus competitors with clearer regulatory outcomes.
Butterfly Network News
BFLY FAQ
What was Butterfly Network’s price range in the past 12 months?
Currently, no data Available
What is Butterfly Network’s market cap?
Butterfly Network’s market cap is $30.02B.
When is Butterfly Network’s upcoming earnings report date?
Butterfly Network’s upcoming earnings report date is Jul 30, 2026 which is in 2 days.
How were Butterfly Network’s earnings last quarter?
Butterfly Network released its earnings results on Apr 30, 2026. The company reported -$0.524 earnings per share for the quarter, beating the consensus estimate of -$0.856 by $0.332.
Is Butterfly Network overvalued?
According to Wall Street analysts Butterfly Network’s price is currently Undervalued.
Does Butterfly Network pay dividends?
Butterfly Network does not currently pay dividends.
What is Butterfly Network’s EPS estimate?
Butterfly Network’s EPS estimate is -0.61.
How many shares outstanding does Butterfly Network have?
Butterfly Network has 234,842,770 shares outstanding.
What happened to Butterfly Network’s price movement after its last earnings report?
Butterfly Network reported an EPS of -$0.524 in its last earnings report, beating expectations of -$0.856. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Butterfly Network?
Currently, no hedge funds are holding shares in MX:BFLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Butterfly Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.25 (― Upside)
$100.25 (― Upside)
Blogger Sentiment
Bullish
MX:BFLY Sentiment 71%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
216.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.20%
Trailing 12-Months
Company Description
Butterfly Network
Butterfly Network, Inc. functions as a digital health enterprise, specializing in the invention, production, and global commercialization of cutting-edge ultrasound imaging technologies for both domestic and international markets. The company's innovative product portfolio includes the portable Butterfly iQ, a versatile single-probe system capable of whole-body ultrasound imaging, and the Butterfly iQ+, a point-of-care ultrasound device engineered to connect effortlessly with smartphones, tablets, and existing hospital computer networks. Additionally, Butterfly Blueprint is offered as a comprehensive, system-wide ultrasound platform that seamlessly integrates its proprietary Compass software into a healthcare provider's clinical and administrative infrastructure. These ultrasound systems, encompassing probes, related accessories, and software subscriptions, are supplied to healthcare systems, individual physicians, and other medical professionals through a multi-channel distribution strategy that includes a direct sales force, a network of distributors, and an e-commerce platform. Beyond its hardware, Butterfly Network provides a suite of cloud-based software solutions for healthcare organizations. These offerings feature teleguidance services, interactive in-app educational modules, and structured training programs delivered via its Butterfly Academy software, all complemented by dedicated clinical support and services. Established in 2011, Butterfly Network, Inc. has its corporate headquarters situated in Guilford, Connecticut.
BFLY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and commercial highlights — double‑digit revenue growth, margin expansion, meaningful Embedded revenue acceleration, major FDA AI clearance, enterprise software traction and product roadmap visibility — while acknowledging remaining challenges: continued adjusted EBITDA losses, reliance on higher‑end device mix, timing and concentration risks in Embedded and Home rollouts, and regulatory/legal timing in the EU. On balance, the positives (growth, margin improvement, product/regulatory milestones and sizable cash balance) outweigh the lowlights, with management reiterating guidance and emphasizing disciplined investment toward scalable opportunities.View all MX:BFLY earnings summaries